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Background: Estimates of influenza and respiratory syncytial virus (RSV) burden must be periodically updated to
inform public health strategies. We estimated seasonal influenza- and RSV-attributable hospitalizations in the US
from 1997 to 2009 according to age and risk status (NCT01599390).
Methods: Multiple linear regression modelling was used to attribute hospitalizations to influenza or RSV using
virological surveillance and hospitalization data. Hospitalization data were obtained from the US Nationwide Inpatient
Sample and virology data were obtained from FluView (Centers for Disease Control and Prevention). Outcomes included
any mention of ICD-coded respiratory disease and cardiorespiratory disease diagnoses. We also explored a broader
definition of respiratory disease that included mention of relevant respiratory sign/symptoms and viral infection
(“respiratory broad”).
Results: Applying the respiratory broad outcome, our model attributed ~300,000 and ~200,000 hospitalizations to
influenza and RSV, respectively. Influenza A/H3N2 was the predominant cause of influenza-related hospitalizations in
most seasons, except in three seasons when influenza B was dominant; likewise, A/H3N2 caused most influenza-related
hospitalizations in all age segments, except in children <18 years where the relative contribution of A/H3N2 and B was
similar. Most influenza A- and B-related hospitalizations occurred in seniors while approximately one half and one third
of all RSV-related events occurred in children 0–4 years and seniors 65+ years, respectively. High-risk status was
associated with higher risk of both influenza- and RSV-attributable hospitalizations in adults, but not in children.
Conclusions: Our study assessed the burden of influenza and RSV, information that is important for both cost
effectiveness studies and for prioritization of the development of antivirals and vaccines. For seniors, we found that the
burdens of influenza and RSV were both substantial. Among children <18 years, about half of all influenza hospitalizations
were due to influenza B, most occurring in children without noted risk conditions. RSV hospitalizations among children
were confined to those 0–4 years. Our study also demonstrated the importance of the outcome used to estimate
hospitalization burden. Our findings highlight the burden of influenza among children regardless of risk status and
underscore the prevalence of RSV infections among both young children and older adults.
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Viral respiratory illnesses such as influenza and respira-
tory syncytial virus (RSV) impose a substantial burden
of hospitalization [1–5]. Influenza has a disproportionate
impact on the young, older adults, and persons with
underlying high risk medical conditions [1, 2]. Clinical
manifestations of influenza virus infection range from
asymptomatic or mild upper respiratory illness to severe
lower respiratory tract disease or exacerbation of chronic
respiratory and cardiac disease. The clinical impact of
influenza is not confined to respiratory conditions. In
young children in particular, the clinical presentation of
influenza can be diverse, and may include gastrointes-
tinal symptoms and febrile convulsions [6]. In adults, ex-
cess cardiovascular outcomes have been attributed to
influenza [7]. The burden of RSV in young children has
long been recognized [3–5], and more recent studies
have also identified a substantial burden in older adults
[8–10]. Clinical manifestations of RSV infection range
from sinusitis and otitis media to bronchiolitis and
pneumonia.
Because the burden of seasonal influenza hospitaliza-
tions is difficult to assess directly, historically it has been
estimated by statistically modeling excess wintertime
health-related outcomes over the background rates of the
same outcomes recorded outside the wintertime period
[11]. The US Centers for Disease Control and Prevention
(CDC) has applied a variety of statistical modeling tech-
niques over the past decades to derive these estimates.
More recently, virological surveillance-guided multiple re-
gression models that include International Classification
of Disease (ICD)-coded outcomes data as additional
model variables have been used to derive pathogen-
specific estimates of disease burden, including the burden
of RSV. The primary advantage of this approach is that
the specific and concomitant burden of disease associated
with multiple pathogens is estimated while controlling for
other disease drivers [12–14].
The burden of influenza varies from season to season
and from decade to decade, both overall and in its impact
on different age groups, depending in part on the domin-
ant virus type or subtypes in circulation [15]. Influenza A/
H1N1 and A/H3N2 viruses have co-circulated for the past
three decades; although A/H3N2 has caused most influ-
enza A illness over this period, A/H1N1 has predominated
periodically [16]. Two distinct lineages of the influenza B
virus, Victoria and Yamagata, have co-circulated since at
least 1983. In the 1990s, the Victoria lineage was not de-
tected in North America, but re-emerged during 2001
[17]. Both lineages have subsequently co-circulated or al-
ternated. Suboptimal vaccine protection might occur in
seasons where the predominant influenza B virus is from
the lineage that is not included in the trivalent seasonal in-
fluenza vaccine [18, 19].To inform vaccination strategies and to prompt accel-
erated development of novel vaccine technologies, it is
critical to thoroughly characterize evolving epidemio-
logical patterns of virus circulation and the burden of
viral illness. In the present study, we estimated the bur-
den of influenza- and RSV-associated hospitalizations in
the US between 1997 and 2009. The study had multiple
aims. Firstly, it evaluated the relative burden of influenza
versus RSV. Secondly, it evaluated the relative burden of
influenza A versus influenza B, which is important in
assessing the value of the quadrivalent influenza vaccine.
Thirdly, it evaluated the burden of illness by age and risk
status. Individuals at high risk, including those who are
elderly, immunocompromised and chronically ill, gener-
ally experience higher rates of severe outcomes from
viral infections and are usually prioritized for vaccin-
ation [20]. Finally, to better estimate the burden of influ-
enza and RSV disease, the study used an outcome
introduced in a related study of influenza- and RSV-
associated mortality [21], “respiratory disease broadly de-
fined” (“respiratory broad”), which may provide a better
balance of sensitivity and specificity compared with esti-
mates derived using classical definitions.
Methods
The objective of this retrospective database analysis
(NCT01599390) was to estimate the numbers and rates of
hospitalization attributable to influenza and RSV in the
US, stratified by age and risk status, for 12 winter seasons.
Total influenza- and RSV-attributable hospitalization and
the relative contribution of the different influenza types
and subtypes were assessed. The analytical approach, as
previously described [21], used multiple linear regression
modelling of time series data extracted from multiple
healthcare and virus surveillance databases. The analysis
used several definitions of influenza- and RSV-related
clinical outcomes, and the model attributed a proportion
of each outcome to either influenza or RSV.
Study population and hospitalization data
The hospitalization data source was the US Nationwide
Inpatient Sample (NIS). All subjects of any age who were
recorded in the NIS during the period 1st October 1997
to 31st March 2009 were included. Data recorded after
31st March 2009 were excluded to avoid bias associated
with the circulation of the 2009 A/H1N1 pandemic in-
fluenza virus. Data included demographic, geographic,
and ICD-coded information including discharge diagno-
sis and co-morbid conditions. Records were excluded if
they had data missing from the age, primary discharge
diagnosis, or admission month fields. Hospitalizations
were classified according to ICD codes (Table 1).
Informed consent was not required as this was an anon-
ymized database study.
Table 1 Definition of hospitalization outcomes expressed in
ICD9 codes
Outcome ICD9 codes
Pneumonia and influenza 480-488





ICD International Classification of Diseases
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of all discharge records from a 20% sample of US hospi-
tals, chosen to be representative of the US as a whole
and four US regions. Details of the NIS are available at
http://www.hcup-us.ahrq.gov/nisoverview.jsp. Monthly
counts of hospitalizations were extracted, stratified by
age (0-4, 5-17, 18-49, 50-64, 65-74, 75+ years), region,
discharge status (dead or alive), and risk status (high or
low). The risk status of each subject was determined
from co-morbidity diagnosis codes listed. Persons were
considered at high risk if any of the following underlying
medical conditions known to increase risk of complica-
tions of influenza were mentioned: chronic obstructive
pulmonary disease, cardiovascular disorders, kidney dis-
orders, diabetes, immunosuppression, liver disorders,
stroke, and central nervous system disorders. Denomin-
ator data for age-risk strata were incorporated into the
study database, and incidence rates were determined for
each outcome by 100,000 population. To calculate rates
for the high risk and low risk populations, data from the
National Health Information Survey (NHIS) was used.
These data have been collected by the US Census
Bureau through personal household interviews for many
years. The proportions of persons answering “yes” to any
condition corresponding to the study’s high risk defini-
tions provided weights used to estimate the prevalence
of the high risk status in the population.
Compliance with relevant legal requirements for data
privacy was ensured through the anonymization and de-
identification of the data. Specifically, the patient infor-
mation in the NIS data contained no personally identifi-
able information. As it was not possible to connect any
data with any personally identifiable information, no pa-
tient informed consent was required. Similarly, ethics
approval was not sought for this retrospective database
study of anonymized data.
Definition of outcomes
The study included a variety of hospitalization out-
comes, ranging from narrow to broad. Five outcomes
are reported in this paper: (i) pneumonia and influenza
(P&I); (ii) a novel outcome referred to as respiratorydisease broadly defined which includes respiratory dis-
eases, cough, breathing abnormalities, fever, and viral in-
fections not otherwise specified (hereafter referred to as
respiratory broad); (iii) respiratory; (iv) cardiorespiratory;
(v) sepsis (Table 1). In the NIS, both primary and sec-
ondary diagnoses are registered. The respiratory codes
included all respiratory illnesses, while the cardiorespira-
tory codes also included all cardiovascular disorders; a
complete list can be found at http://icd9cm.chrisendres.com.
For all outcomes, two analyses were conducted, one
including cases with any mention of the relevant ICD
codes as a primary or secondary diagnosis and the
other including only cases with the relevant ICD
codes mentioned as the primary diagnosis.Virology data
The virology data source was the weekly influenza update,
FluView, published by the CDC [22]. The weekly numbers
of respiratory samples that were laboratory-confirmed as
positive for influenza A and B types and subtypes in each
of the four US statistical census regions were obtained.
These data represent combined reporting to the CDC of
approximately 85 World Health Organization (WHO) col-
laborating laboratories and 60 National Respiratory and
Enteric Virus Surveillance System (NREVSS) laboratories.
Data were collected between week 40 of the first calendar
year of a season and up to and including week 20 of the
second calendar year of the season. Weekly RSV surveil-
lance data (counts of laboratory-confirmed RSV viruses,
from each region and nationally each week) were obtained
from the NREVSS [23]. Age-specific virological data were
not available.Statistical analysis
Preparation of time series data
The statistical modelling approach to attribute ‘excess
hospitalizations’ using national time series has only been
expanded to include RSV in the early 2000s [12]. Weekly
influenza and RSV virology time series were constructed
by dividing the weekly total of influenza (according to
type and subtype) or RSV positive samples by the sea-
sonal total of influenza or RSV tests. Hospitalization
data were available only by month, whilst virus surveil-
lance data were available by week. To account for this,
weekly values of aggregate hospitalization outcome
counts were estimated by interpolation (SAS ‘Proc
Expand’ with spline). Each week’s virus surveillance data
were appended to the corresponding week’s hospitalization
outcome estimates. Given that presentation with influenza
can occur some time after the onset of infection [15], we
assessed whether lagging the virological data by 1–3 weeks
would improve model fit. As model fit was not improved,
we did not introduce a lag.
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of admissions in the weighted NIS sample falling into a
particular age group in a particular year could vary sub-
stantially. This occurred because hospitals joined and/or
left the NIS data supply effort, the fact that catchment
populations of hospitals had varying age profiles, and
the lack of age-stratification in the NIS weighting
scheme. This presented only a minor problem for com-
mon outcomes. However, the scarcer an outcome was
within an age group (e.g. “cardiovascular” in younger
groups), the more likely it was that year to year fluctu-
ation would cause problems in modeling. The weighted
percentage of hospital admissions (all-cause) in each age
group within each region for each year was compared
with the annual total population of each age group
within the corresponding region. The NIS weights were
then adjusted so that the annual changes in hospital ad-
missions in each region and age group corresponded to
the annual changes in the corresponding population. For
example, if the proportion of the population in a par-
ticular age group and particular region was 20% in 1998
and 20.5% in 1999, and the proportion of hospital ad-
missions in the same age group and region was 10% in
1998 and 11% in 1999, then the population share for
that age group and region expanded by 2.5% over the
year, whilst the hospital admissions share increased by
10%. Observing that, for the most part, admissions
trends within an age group and region did tend to track
those in the population, the admissions for each year
were reweighted within each region and age group so
that, within a region, the change in admissions share for
an age group corresponded to the change in population
share for that age group. The result was a partial
smoothing of the annual total admissions series for the
outcomes analyzed. For most age groups, regions and
year-to-year transitions, the reweighting was minimal.
Regression model
The analysis, similar to our previously published ap-
proach for estimating influenza mortality [21], was per-
formed using SAS version 9.3. For each outcome, census
region, age, and risk stratum, the same multiple linear
regression model form was applied. The model form
used is given by the equation:
Y ¼ β1 þ β2 RSVð Þ þ β3 Influenza A=H1ð Þ
þ β4 Influenza A=H3ð Þ þ β5 Influenza Bð Þ
þ β6 sin 2πt=52:18ð Þ þ β7 cos 2πt=52:18ð Þ
þ β8tþ β9t2 þ β10t3
where Y is the incidence (rate) of outcome for each time
period t, RSV and influenza are the proportion of labora-
tory isolates during t (week), sin and cos are harmonicfunctions of t (week), and the remaining terms track
other types of secular trends in the data. The time
period t used in the model is a running index of weeks
starting 1st October 1997 and ending 31st March 2009.
The RSV term controls for the effect of concurrent RSV
epidemics. The relative goodness of fit was used to iden-
tify the best model form across all age groups by select-
ing the form with the highest adjusted R2; this model
form was then applied across all strata. We found a sub-
stantial improvement in the adjusted R2 value when
introducing the virology terms into the base secular
model. Visual inspection showed that spikes during the
winter-seasonal period are captured well by the model.
Incidence rates for each outcome per 100,000 popula-
tion were calculated using census data. National Health
Information Survey data were used to provide estimates
of the prevalence of high risk status in the general popu-
lation. For each regional seasonal burden estimate and
for each influenza type/subtype and for RSV, each
weekly point estimate was multiplied by the regression
coefficient, then the weekly estimates were aggregated
over the entire season.
The overall national burden attributable to each
pathogen was determined by aggregating all positive re-
gional point estimates within each stratum by adding the
counts and converting to rates. Negative burden esti-




The model fit was generally good in older age groups
and in young children aged 0–4 years. The adjusted
R2 ranged for the respiratory broad outcome from a
high of 0.90 in the 75+ years age group to a low of
0.36 in the 5-17 years age group, which is the group
with the smallest numbers of hospitalizations and
thus the most likely to show a lower fit. In all cases,
the addition of the virology terms to the model in-
creased R2, and usually by a substantial amount. For
example, for the respiratory broad outcome, adding
the virology terms increased the adjusted R2 by 7% to
70%. Results were similar for the cardiorespiratory
outcome, and even better for the P&I outcome, with
R2 ranging from 0.67 to 0.93 across age groups.
Estimates of hospitalization burden using various outcomes
Outcomes with the relevant ICD codes among any of the
discharge diagnoses (“any mention”)
Over the 12 winter seasons during 1997–2009, the
model estimated an average seasonal burden of 297,548
(range 123,077–473,027) influenza-attributable hospitali-
zations when applied to time series using the respiratory
broad outcome (any mention); this is equivalent to a
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(Table 2). The highest number of influenza-attributable
hospitalizations was associated with influenza A/H3N2
(184,995 [3750–392,352]; 64 per 100,000 population),
followed by influenza B (88,775 [2882–188,309]; 30 per
100,000 population) and influenza A/H1N1 (23,778
[49–77,994]; 8 per 100,000 population). The hospitalization
burden of RSV was also high, although lower than the bur-
den of influenza: 186,155 (151,326–218,476) hospitaliza-
tions, equivalent to an annual mean rate of 64 per 100,000
population (Table 2). As expected, the number of influenza-
and RSV-attributable hospitalizations varied depending
upon the outcome used (Table 2).Outcomes with the relevant ICD codes as the primary diagnosis
As expected, the model estimated fewer influenza- and
RSV-attributable hospitalizations using the relevant ICD
codes mentioned specifically as the primary diagnosis.
For influenza, the pattern of hospitalization for the pri-
mary diagnosis was similar to that of any mention: the
highest number of hospitalizations was associated with
the cardiorespiratory outcome (230,834 [range 94,469–
310,270]), followed by respiratory broad (190,795
[52,036–279,807]), respiratory (185,005 [50,038–272,219]),
and P&I (99,624 [20,428–155,443]) (Table 2). The number
of RSV-attributable hospitalizations was lowest for the
P&I outcome (56,790 [46,316–77,900]), but was similar
for the cardiorespiratory (142,301 [111,992–184,119]),
respiratory broad (152,034 [122,280–193,118]) and re-
spiratory outcomes (149,307 [119,731–188,735]). Influ-
enza- and RSV-attributable hospitalizations for the sepsis
(primary) outcome were 7304 (3471–17,020) and 2526
(1716–4614), respectively (Table 2).Seasonal variation in hospitalization burden
The total number of influenza-attributable hospitaliza-
tions with the respiratory broad outcome (any mention)
varied considerably across the 12 seasons covered by the
model (Additional file 1: Table S1). In contrast, annual
numbers of RSV-attributable hospitalizations varied less
over the same period. Nonetheless, in an average season,
influenza accounted for 62% of all influenza- and RSV-
attributable hospitalizations (Fig. 1).
Although influenza A/H3N2 was predominant in most
seasons, influenza B was predominant in three of the 12
seasons, and was associated with 74% of influenza-
attributable hospitalizations in 2000/01, 65% in 2002/03,
and 56% in 2008/09 (Fig. 1; Additional file 1: Table S1).
In a further five seasons (1998/99, 2004/05, 2005/06,
2006/07, 2007/08), influenza B was responsible for ap-
proximately 30–40% of influenza-attributable hospitali-
zations (Fig. 1; Additional file 1: Table S1).Age-specific estimates of hospitalization burden
The average seasonal burden of influenza-attributable
hospitalizations meeting the respiratory broad (any men-
tion) outcome varied across age groups (Table 3), with
approximately one half occurring in adults over 65 years
of age, and one third in adults over 75 years of age. The
number of hospitalizations was lower in children, with
the 0-4 and 5–17 year age groups accounting for ap-
proximately 8% and 4% of the overall burden, respect-
ively. Influenza A was predominant in all age groups,
although the distribution of influenza A and B hospitali-
zations was about 1:1 in both pediatric age groups. In
contrast, in seniors 75+ years of age, the ratio was ap-
proximately 4:1, consistent with a far higher impact of
influenza A/H3N2 in older adults (Table 3 and Fig. 2).
Influenza A/H1N1 was responsible for the fewest attrib-
utable hospitalizations in all age groups (Fig. 2).
In contrast, approximately one half of all RSV-
attributable hospitalizations occurred in children aged
0–4 years and approximately one third in adults aged 65
+ years, while no RSV-attributable hospitalizations oc-
curred in children aged 5–17 years (Table 3; Fig. 2). The
RSV burden in seniors over 65 years was substantial, ac-
counting for more than 60,000 hospitalizations in an
average year (Table 3; Fig. 2), and with far less seasonal
variability than influenza (data not shown).
Compared with RSV, influenza (all subtypes) accounted
for a higher proportion of hospitalizations in all age
groups, except children 0–4 years of age, where RSV
accounted for 80% of hospitalizations identified by the re-
spiratory broad outcome (Fig. 2). Influenza was respon-
sible for approximately five times as many hospitalizations
as RSV in the 18–49 year age group, four times as many
in the 50–64 year age group, three times as many in the
65–74 year age group, and twice as many in the 75+ year
age group (Table 3).
Differences in hospitalization burden according to risk
status
Overall, high risk status was associated with higher
numbers of influenza-attributable hospitalizations. Ap-
plying the respiratory broad outcome (any mention),
the relative hospitalization rate for high versus low
risk status was 7.7 (Table 4). However, the pattern
was not consistent between age groups. In children,
high risk status was associated with fewer influenza-
attributable hospitalizations compared with low risk
status. The relative rate of influenza-attributable hos-
pitalizations in high versus low risk adults increased
with age, peaking at age 50–64 years with a rate ratio
of 8.9, followed by a decline to 7.2 in age 65–74 years
and further to 4.9 in age 75+ years (Table 4). Similar
findings were observed for the number of hospitaliza-
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Fig. 1 Proportion of total hospitalizations attributable to influenza and RSV by season in the US, 1997–2009 (respiratory broad outcome, any mention)
Matias et al. BMC Public Health  (2017) 17:271 Page 7 of 14Overall, high risk versus low risk status was also associ-
ated with a higher rate of RSV-attributable hospitalization,
with a rate ratio of 1.9 (Table 4). As observed for
influenza-attributable hospitalization, the pattern for RSV
was inconsistent across age groups. Children up to
18 years of age with high risk status had a lower RSV
hospitalization rate than children with low risk status (rate
ratio below 1) (Table 4). In adults, RSV-attributable
hospitalization rate increased with age in high risk individ-
uals relative to low risk individuals up to age 65–74 years
(rate ratio 11.1), followed by a decline to 5.0 in age 75+
years. A similar pattern was observed for the number of
hospitalizations (Additional file 1: Table S2).
Discussion
In our study, we applied a multiple regression modeling
strategy that has long been employed to estimate the sea-
sonal excess in hospitalizations attributable to influenza
and RSV. We also tested the effect of using a variety of
diagnoses outcomes (with varying sensitivity and specifi-
city) beyond the traditional ICD code ranges of cardiac
and respiratory diseases. In addition, we examined
pediatric age groups more closely and sought to stratify
hospitalization by influenza risk status (e.g. mention of
certain chronic underlying illnesses). Using an expanded
respiratory disease outcome (respiratory broad) that in-
cluded respiratory signs/symptoms and other viral dis-
eases, we estimated that an average US winter season has
~300,000 influenza-related hospitalization events. The risk
of hospitalization for influenza was most pronounced in
young children and older adults, with the highest burden
occurring in the oldest age group, age 75+ years. The an-
nual relative impact of influenza A and B varied substan-
tially during the study period. Using the same respiratory
broad outcome, the model also attributed 200,000 winter-
seasonal hospitalizations to RSV, also mostly in young
children and older adults. Our results confirm and
expand on the findings of a recent CDC study regard-
ing the burden of influenza- and RSV-related hospi-
talizations in the US [2].In line with what has been reported in other studies,
seasons dominated by circulation of A/H3N2 viruses re-
corded the highest numbers of influenza-related hospi-
talizations [1, 2]. The A/H3N2 virus was associated with
the majority of influenza-related hospitalizations during
our study period. However, we noted that an unusually
high 56–74% of influenza hospitalizations were attribut-
able to influenza B during seasons 2000/01, 2002/03,
and 2008/09 in which influenza B accounted for 34–47%
of all circulating influenza viruses [24]. This implies that
simply considering average burden estimates over time
misses the fact that an influenza B-dominated season
can be associated with considerable influenza burden.
This point is particularly important for pediatric age
groups for whom the influenza hospitalization burden
was as high in a predominantly influenza B season as
in any season dominated by influenza A/H3N2 vi-
ruses. These excess hospitalizations mostly occurred
among children without known underlying medical
conditions listed on their hospital discharge records.
This finding is consistent with current US and WHO
policies of recommending vaccination for children for
influenza regardless of risk status, in addition to the
traditional recommendations of high risk and senior
populations [25, 26].
Our statistical modelling approach included time
series of influenza and RSV laboratory-confirmed pat-
terns and thus allowed the simultaneous attribution of
hospitalizations to each influenza type/subtype and to
RSV. This statistical “excess hospitalizations” approach
using national time series of hospitalizations has only in
the last decade or so been expanded to include RSV.
Recently, evidence of RSV burden was reported by two
prospective US studies of laboratory-confirmed influenza
and RSV which demonstrated a similar (1:1) ratio of
hospitalizations attributable to influenza and RSV in se-
niors [9, 10]. However, both of those studies were set in
local populations (and over fewer seasons) and therefore
a national estimate that also allowed computation of the
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Fig. 2 Proportion of total hospitalizations attributable to influenza and RSV by age in the US, 1997–2009 (respiratory broad outcome, any mention)
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burden of RSV-attributable hospitalizations is indeed
substantial, and that its magnitude is nearly half that of
influenza in adults aged 65 years and older, and particu-
larly high in those aged 75+ years. Our findings on RSV
burden are in excellent agreement with those of Zhou
and colleagues [2], as both studies found a substantial
RSV burden in seniors but not as high as that of influ-
enza in an average season. As seniors are rarely tested
for RSV, additional data on indirect measures of the RSV
burden in seniors are needed to guide RSV vaccine
development and set recommendations for the RSV
vaccines that are expected in the coming years.
Not surprisingly, in children under 5 years of age, the
hospitalization burden of RSV was four times higher
than that of influenza (ratio 4:1). We found very low
RSV-related hospitalization in children aged 5–17 years,
as observed in previous studies [27, 28]. As for influenza,
most pediatric RSV hospitalizations occurred in children
without a documented risk condition for influenza; how-
ever, we could not investigate known important risk fac-
tors such as premature birth and birth month [29]. Our
findings regarding the relative burden of RSV-and
influenza-attributable hospitalization across overlapping
age groups are also in agreement with other modeling
studies [2, 8], but ours is the only study to investigate
the RSV burden both in school children and in older se-
niors aged 75+ years. A caveat to our data is that most
RSV hospitalizations occur in children less than 1 year
of age [30], but we did not stratify the <5 years age
group to give more age-specific estimates. Stratification
of this age group would also be useful for influenza
estimates.
We noted that the relative burden of influenza B ver-
sus A was greatest in both pediatric age groups 0–4 and
5–17 years of age; for these age groups, influenza hospi-
talizations were split approximately equally between in-
fluenza B and A. Overall, the number of hospitalizations
was low in the 5–17 year age group regardless of influ-
enza type. Zhou and colleagues also found higher ratesof hospitalization attributable to influenza B than to in-
fluenza A in children 1–4 years of age, but did not study
children aged 5–17 years as a separate age group [2]. In
individuals 5–49 years of years, Zhou and colleagues
found approximately equal rates of hospitalization at-
tributable to influenza A and B [2].
An important goal of our study was to generate a na-
tional estimate of influenza- and RSV-attributable hospi-
talizations according to medical risk status across all age
segments; this aspect was not evaluated in previous
studies of US hospitalization burden [1, 2]. Influenza
vaccine recommendations around the world account for
medical risk status based on the presence of co-morbid
conditions. We found our findings in children to be sur-
prising. Although an elevated risk of severe health out-
comes in high versus low risk children with influenza is
well established in the observational literature [31, 32],
we observed the opposite – high risk children had lower
hospitalization rates than low risk children. The relative
risk of influenza hospitalization in high risk versus
low risk children (ratio high risk/low risk) was 0.2 for
children 0–4 years of age and 0.6 for those 5–17
years of age. A similar observation has been made by
Cromer and colleagues for children 0–4 years of age
in an analysis of influenza burden in England, with a
relative risk of 0.7 for children <6 months of age and
0.9 for those aged 6 months to 4 years [33]. However,
Cromer and colleagues’ results contrast with ours for
older children aged 5–17 years; in their study, high
risk children had a higher burden of influenza
hospitalization than low risk children (relative risk
5.7) [33]. In our previous study of influenza- and
RSV-related mortality, we also observed higher death
rates in low versus high risk children aged 0–4 years,
and approximately equal death rates in low and high
risk children aged 5–17 years [21]. There is no
obvious explanation for this finding, but it may be re-
lated to under-identification and/or under-reporting
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come used to estimate the hospital burden. The trad-
itional P&I and respiratory outcomes are very specific in
capturing the influenza-attributable burden, but are not
particularly sensitive. In contrast, the classical cardiore-
spiratory outcome used by Zhou and colleagues [2] has,
by definition, a lower specificity due to the inclusion of
many cardiac disease events not related to influenza.
Thus, estimates of burden using the P&I and respiratory
outcomes will be lower than estimates using the cardio-
respiratory outcome. The respiratory broad outcome in-
cluded any mention of respiratory codes, as well as any
mention of respiratory signs/symptoms and unspecified
virus illness. The inspiration to add codes outside the
typical ICD code range used in classical studies came
from a study finding that ICD9 code 079.99 (viral dis-
ease, unspecified) was the code most often associated
with oseltamivir prescription, despite the fact that suspi-
cion of influenza must have prompted the prescription
[34]. This finding suggests that likely influenza-related
admissions would often be missed using the traditional
code range of ICD9 460–519 for respiratory diseases. In
our study, as expected, influenza-attributable hospitali-
zations increased as outcomes became more sensitive
and less specific (in rank order P&I, classic respiratory,
respiratory broad, cardiorespiratory). We suggest that
the respiratory broad outcome provides a case definition
that is both sensitive and specific, and thus represents a
better choice than traditional outcomes.
To further investigate the potential for exclusion of
important hospitalization events using classical out-
comes, we also applied the model to time series of sepsis
and found that approximately 24,000 sepsis hospitaliza-
tions in an average season were attributable to influenza
or RSV. Even though this is not a high number com-
pared with the joint seasonal burden of 500,000 hospital-
izations associated with the two viruses, the economic
burden of sepsis is considerable [35]. This suggests that
such outcomes should also be counted and that consid-
erable cost-savings could be made assuming that some
sepsis hospitalizations could be prevented by vaccination
against influenza or RSV. In principle, such estimations
can be done for other disease outcomes with winter-
seasonal patterns.
When comparing our hospitalization rates with those
of Zhou and colleagues [2], we see multiple differences
in outcome definitions, statistical modeling approach
(negative binomial versus linear regression), data source
(we used the Agency for Healthcare Research and Qual-
ity’s NIS database, while Zhou and colleagues used the
State Inpatient Databases and projected rates to non-
participating States), and use of secondary as well as
primary diagnoses in our study. Using primary mention
of the classical cardiorespiratory outcome definition,Zhou and colleagues estimated an annual influenza-
attributable hospitalization rate of 64 per 100,000 popula-
tion [2]. Using the corresponding outcome definition, our
estimates were slightly higher at 80 per 100,000 popula-
tion. In an earlier CDC study, Thompson and colleagues
reported a corresponding estimate of 88 per 100,000 [1].
For RSV, the hospitalization rate based on primary men-
tion of the cardiorespiratory outcome was estimated at 55
per 100,000 by Zhou and colleagues [2] and at 49 per
100,000 by our analysis. Thus, there is broad agreement
on the overall burden and pattern of influenza and RSV
disease when similar comparisons are made.
Our study had several limitations. Firstly, hospitalization
data were only available by month for non-governmental
researchers, whilst virus surveillance data were available
by week. We dealt with this by interpolating monthly data
into weekly data. It is possible that this approach may have
overestimated the precision of hospitalization rates. In
addition, the lack of weekly data may have resulted in the
model being unable to discriminate precisely the burden
of influenza and RSV in seasons where there was signifi-
cant overlap of the two epidemics, especially in children
where viral coinfections (including with respiratory viruses
other than RSV and influenza) are common. Secondly, al-
though the relative distribution of influenza A, influenza
B, and RSV is known to vary by age, US age-specific viro-
logical data were not available; instead, we used all-age
composite virological data to guide the timing of the epi-
demic in the model. However, in sensitivity analyses (not
shown), lagging outcomes by age strata relative to virus
circulation did not improve model fit, suggesting that the
timing at least was adequate, although the relative sizes of
the estimates by age group might be affected. Thirdly, risk
status could only be determined by the presence or ab-
sence of ICD codes during a single hospitalization episode,
and assignment of risk status critically depended upon
whether the physician had mentioned among the dis-
charge diagnoses any existing underlying disease. In clin-
ical practice, it is likely that the physician would fail to
mention some underlying diseases or factors that are cate-
gorized as high risk; indeed some important risk factors
such as obesity or pregnancy are not reported reliably
unless assessed prospectively. This may have led to mis-
assignment of risk status. In contrast, symptoms that were
part of the influenza illness may have been listed as under-
lying disease, leading to overestimation of risk. We could
not investigate other known risk factors such as prema-
ture birth and obesity, which were unlikely to be men-
tioned by physicians on discharge. Fourthly, negative
burden estimates were not included in the aggregations as
they are not biologically plausible. In cases where the coef-
ficient indicates a very small attributable burden from one
of the viral terms, the estimate may be negative due to the
inherent lack of precision. This problem is particularly
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circulate, and for nonspecific outcomes such as cardiore-
spiratory illness. Setting the negative estimates to zero
could have resulted in overestimation of hospitalizations.
However, we conducted a sensitivity analysis comparing
estimates obtained when we did or did not set negative
values to zero. For influenza A/H3N2 and B, there were
no negative estimates to set to zero. For A/H1N1, where
the burden is considerably smaller, we found that setting
the estimates to zero did have a substantial effect.
However, the net effect on the total influenza burden
was limited, because the A/H1N1 virus causes only a
small proportion of the total influenza-attributable
hospitalization. Finally, although our study used na-
tional data and employed a linear regression model, it
was limited by the ICD-coded information on each
discharge record. Thus, some true patients may have
been missed, while others may have been miscoded
and wrongly included. It should be noted that the
clinical manifestations of RSV infection are very
broad, and that atypical presentation of influenza is
common in young children; some of these presenta-
tions would have been likely to be assigned ICD
codes not included in any of our definitions. Moreover,
ICD coding practices and criteria for hospitalization can
change over time and thus affect the estimates. For ex-
ample, diagnosis codes in administrative data are often
assigned as part of billing and cost reimbursement proce-
dures, allowing changing financial incentives to bias
trends in coding practices. It seems unlikely that such
forces will become less important in the future, although
improvements in diagnostic testing might make the codes
assigned to patients with infectious diseases more accur-
ate. No system will allow complete accuracy in assignment
of diagnostic codes. Although the two US laboratory-
based studies on RSV burden did not have the problem of
assignment of diagnostic codes to contend with, they were
limited by the use of local data, the small populations
under study and the possibility that a hospitalization was
not directly attributable to RSV infection [9, 10].
There are also some caveats to our statistical method-
ology. All indirect statistical approaches based on retro-
spective data have inherent limitations. For example,
non-infectious factors and pathogens other than influ-
enza and RSV may influence hospitalization, but specific
information on the nature of such influences is unavail-
able. Although a cyclic term was included in the model
to adjust for this, it adds uncertainty to the model esti-
mates in addition to that derived from variability in the
data. In addition, when an outcome occurs at a low
frequency, the assumption of a normally distributed
dependent variable is more likely to be violated. To ad-
dress the problems associated with low frequency data,
some previous analyses have used generalized linearmodels that relax the assumption of a normal distribu-
tion, including discrete probability distributions appro-
priate for count data such as the Poisson regression with
a natural logarithm for the link function [12, 36]. Use of
the logarithm function, however, implies multiplicative
effects of respiratory viruses, which is an unrealistic as-
sumption [37, 38]. It is more likely that co-circulating
strains could result in a reduction of the burden due to
cross-protection [39], competitive exclusion or both.
This makes the additive model more plausible from a
biological and epidemiological perspective [38–40].
Conclusions
This is the first study to model estimates of influenza-
and RSV-attributable hospitalizations in the US accord-
ing to a novel outcome (respiratory broad), and to use
expanded age groups and risk based status across all age
groups. Our findings are in line with and expand upon
other studies that have found a high burden of influ-
enza- and RSV-attributable hospitalization in children,
older adults, and at-risk groups, and add to the growing
evidence for RSV as an important pathogen in adult
hospitalization. We confirmed that seasonal RSV and in-
fluenza hospitalization burden has a U-shaped age-
related pattern, with most hospitalizations occurring in
low risk children and high risk older adults. The study
demonstrated the importance of the outcome used to es-
timate hospitalization burden, and it study adds to the
body of evidence that informs public health policies on
vaccination strategies to control influenza and RSV.
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